Phase IIa Randomized Placebo Controlled Trial: Mesenchymal Stem Cells as a Disease-modifying Therapy for Idiopathic Parkinson's Disease
Public ClinicalTrials.gov record NCT04506073. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-blind, Placebo-controlled Trial of Allogeneic Bone Marrow-derived Mesenchymal Stem Cells as a Disease-modifying Therapy for Idiopathic Parkinson's Disease
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to select the safest and most effective number of repeat doses of allogeneic bone marrow-derived mesenchymal stem cell (MSC) infusions to slow the progression of Parkinson's disease (PD).
Study identification
- NCT ID
- NCT04506073
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 45 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 50 Years to 79 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 8, 2020
- Primary completion
- Jul 29, 2023
- Completion
- Jul 29, 2023
- Last update posted
- Jul 25, 2024
2020 – 2023
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| The University of Texas Health Science Center at Houston | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Parkinson's Disease trials
Other public records listing Parkinson's Disease. Sorted by last update posted; newest first. Not a recommendation.
- NCT07793461: Gastrointestinal Dopamine Decarboxylase and Levodopa Pharmacokinetics Not yet recruiting
- NCT07442747: Neural Mechanisms of Aerobic Exercise Benefits in PD With DBS Recruiting
- NCT05410392: Telemedicine Intervention in Patients With Chronic Pain in PD Active, not recruiting
- NCT04799470: Novel DBS Stimulation Patterns for Treatment of Parkinson's Disease Recruiting
- NCT07703137: NAD Supplementation in Parkinson's Disease Not yet recruiting
- NCT05413291: Natural History Protocol for Movement Disorders Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04506073, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 25, 2024 · Synced Sep 1, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04506073 live on ClinicalTrials.gov.